
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3504496/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	2.2	3,915
2	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2010, 31, 2501-2555.	2.2	2,649
3	Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, The, 2007, 370, 937-948.	13.7	1,329
4	Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. New England Journal of Medicine, 2007, 356, 1030-1039.	27.0	1,182
5	Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet, The, 2012, 379, 1393-1402.	13.7	854
6	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2223-2235.	27.0	843
7	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The. 2018. 392. 940-949.	13.7	555
8	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. New England Journal of Medicine, 2019, 381, 1820-1830.	27.0	523
9	Drug-eluting stent thrombosis. Journal of the American College of Cardiology, 2005, 45, 954-959.	2.8	505
10	Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment. Diabetes, 2005, 54, 2430-2435.	0.6	492
11	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet, The, 2016, 388, 2479-2491.	13.7	451
12	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet, The, 2012, 380, 1482-1490.	13.7	412
13	Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet, The, 2019, 394, 1325-1334.	13.7	406
14	Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients. Circulation, 2005, 112, 2175-2183.	1.6	345
15	Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care** and Thrombosis of the European Society of Cardiology. EuroIntervention, 2013, 8, 1242-1251.	3.2	336
16	Impact of Platelet Reactivity on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Journal of the American College of Cardiology, 2007, 50, 1541-1547.	2.8	335
17	Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. New England Journal of Medicine, 2015, 373, 997-1009.	27.0	334
18	Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet, The, 2018, 391, 41-50.	13.7	307

#	Article	IF	CITATIONS
19	Insulin Therapy Is Associated With Platelet Dysfunction in Patients With Type 2 Diabetes Mellitus on Dual Oral Antiplatelet Treatment. Journal of the American College of Cardiology, 2006, 48, 298-304.	2.8	284
20	Reperfusion therapy for ST elevation acute myocardial infarction 2010/2011: current status in 37 ESC countries. European Heart Journal, 2014, 35, 1957-1970.	2.2	275
21	Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ: British Medical Journal, 2008, 337, a1331-a1331.	2.3	270
22	Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents. Journal of the American College of Cardiology, 2014, 63, 299-307.	2.8	269
23	High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. European Heart Journal, 2004, 25, 1903-1910.	2.2	268
24	Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. European Heart Journal, 2017, 38, 3124-3134.	2.2	244
25	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet, The, 2018, 392, 835-848.	13.7	215
26	Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1895-1900.	2.4	214
27	Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention. Circulation, 2009, 119, 3215-3222.	1.6	213
28	Clinical Outcomes With Drug-Eluting and Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2013, 62, 496-504.	2.8	210
29	Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction—TROFI II trial. European Heart Journal, 2016, 37, 229-240.	2.2	197
30	Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2010, 55, 1139-1146.	2.8	193
31	Very Late Scaffold Thrombosis. Journal of the American College of Cardiology, 2015, 66, 1901-1914.	2.8	186
32	Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet, The, 2016, 387, 357-366.	13.7	174
33	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent. Circulation: Cardiovascular Interventions, 2015, 8, e001441.	3.9	172
34	The 2011-12 pilot European Sentinel Registry of Transcatheter Aortic Valve Implantation: in-hospital results in 4,571 patients. EuroIntervention, 2013, 8, 1362-1371.	3.2	168
35	Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet, The, 2019, 393, 2503-2510.	13.7	166
36	A Randomized Comparison of Sirolimus-Eluting Stent With Balloon Angioplasty in Patients With In-Stent Restenosis. Journal of the American College of Cardiology, 2006, 47, 2152-2160.	2.8	158

#	Article	IF	CITATIONS
37	Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thrombosis Research, 2005, 115, 101-108.	1.7	154
38	Importance of diastolic fractional flow reserve and dobutamine challenge in physiologic assessment of myocardial bridging. Journal of the American College of Cardiology, 2003, 42, 226-233.	2.8	146
39	Clopidogrel Withdrawal Is Associated With Proinflammatory and Prothrombotic Effects in Patients With Diabetes and Coronary Artery Disease. Diabetes, 2006, 55, 780-784.	0.6	146
40	Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent inÂST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison. JACC: Cardiovascular Interventions, 2015, 8, 189-197.	2.9	145
41	Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. Journal of Invasive Cardiology, 2004, 16, 169-74.	0.4	142
42	Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thrombosis Research, 2005, 116, 491-497.	1.7	137
43	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. Journal of the American College of Cardiology, 2017, 69, 2592-2603.	2.8	132
44	Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. EuroIntervention, 2015, 11, 45-52.	3.2	131
45	Influence of Aspirin Resistance on Platelet Function Profiles in Patients on Long-Term Aspirin and Clopidogrel After Percutaneous Coronary Intervention. American Journal of Cardiology, 2006, 97, 38-43.	1.6	117
46	Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis. Heart, 2015, 101, 1395-1405.	2.9	115
47	Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. EuroIntervention, 2017, 12, 2110-2117.	3.2	114
48	Background, Incidence, and Predictors of Antiplatelet Therapy Discontinuation During the First Year After Drug-Eluting Stent Implantation. Circulation, 2010, 122, 1017-1025.	1.6	98
49	Comparison of Newer-Generation Drug-Eluting With Bare-Metal Stents inÂPatients With Acute ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2014, 7, 55-63.	2.9	96
50	Coronary stenting versus balloon angioplasty in small vessels. Journal of the American College of Cardiology, 2004, 43, 1964-1972.	2.8	93
51	Fractional Flow Reserve Derived From Computed Tomographic Angiography in Patients With Multivessel CAD. Journal of the American College of Cardiology, 2018, 71, 2756-2769.	2.8	92
52	Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis. Journal of the American College of Cardiology, 2002, 39, 281-287.	2.8	89
53	PIA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagulation and Fibrinolysis, 2004, 15, 89-93.	1.0	88
54	Vascular Effects of Sirolimus-Eluting Versus Bare-Metal Stents in Diabetic Patients. Journal of the American College of Cardiology, 2006, 47, 2172-2179.	2.8	87

#	Article	IF	CITATIONS
55	Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. BMJ, The, 2014, 349, g6427-g6427.	6.0	82

The EXAMINATION Trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation) Tj ETQq0 0 0.25 BT /Overlock 10 Tr

57	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment–Elevation Myocardial Infarction and Multivessel Disease. Circulation: Cardiovascular Interventions, 2018, 11, e006023.	3.9	80
58	International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19. Journal of the American College of Cardiology, 2021, 77, 2466-2476.	2.8	78
59	Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. Journal of the American College of Cardiology, 2020, 76, 1609-1621.	2.8	75
60	Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction. Circulation, 2019, 140, 1904-1916.	1.6	74
61	Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. European Heart Journal, 2007, 28, 1946-1952.	2.2	73
62	Association of Myocardial T1-Mapping CMR With Hemodynamics and RV Performance in Pulmonary Hypertension. JACC: Cardiovascular Imaging, 2015, 8, 76-82.	5.3	71
63	Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease. JACC: Cardiovascular Interventions, 2019, 12, 2064-2075.	2.9	71
64	Hypothermia in Acute Coronary Syndrome. Journal of the American College of Cardiology, 2013, 61, 686-687.	2.8	69
65	Double Antiplatelet Therapy After Drug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2012, 60, 1333-1339.	2.8	68
66	A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With DiabetesÂMellitus. JACC: Cardiovascular Interventions, 2016, 9, 42-50.	2.9	68
67	Remodeling of atherosclerotic coronary arteries varies in relation to location and composition of plaque. American Journal of Cardiology, 1999, 84, 135-140.	1.6	65
68	Local and general anaesthesia do not influence outcome of transfemoral aortic valve implantation. International Journal of Cardiology, 2014, 177, 448-454.	1.7	65
69	Selected CD133 ⁺ Progenitor Cells to Promote Angiogenesis in Patients With Refractory Angina. Circulation Research, 2014, 115, 950-960.	4.5	63
70	Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent WithÂaÂDurable Polymer Everolimus-Eluting Stent. JACC: Cardiovascular Interventions, 2018, 11, 995-1002.	2.9	63
71	Intravascular Brachytherapy Versus Drug-Eluting Stents for the Treatment of Patients With Drug-Eluting Stent Restenosis. American Journal of Cardiology, 2006, 98, 1340-1344.	1.6	61
72	Variability in Platelet Aggregation Following Sustained Aspirin and Clopidogrel Treatment in Patients With Coronary Heart Disease and Influence of the 807 C/T Polymorphism of the Glycoprotein Ia Gene. American Journal of Cardiology, 2005, 96, 1095-1099.	1.6	60

#	Article	IF	CITATIONS
73	Randomized Comparison of Sirolimus-Eluting and Everolimus-Eluting Coronary Stents in the Treatment of Total Coronary Occlusions. Circulation: Cardiovascular Interventions, 2013, 6, 21-28.	3.9	60
74	Bypass Surgery or Stenting for LeftÂMainÂCoronary Artery Disease in PatientsÂWith Diabetes. Journal of the American College of Cardiology, 2019, 73, 1616-1628.	2.8	60
75	Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 58, 30-39.	2.8	58
76	Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2013, 310, 1145.	7.4	58
77	Outcomes After Coronary Stenting or Bypass Surgery for Men and Women With Unprotected Left Main Disease. JACC: Cardiovascular Interventions, 2018, 11, 1234-1243.	2.9	58
78	Disparate miRNA expression in serum and plasma of patients with acute myocardial infarction: a systematic and paired comparative analysis. Scientific Reports, 2020, 10, 5373.	3.3	58
79	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. Circulation, 2019, 140, 1921-1932.	1.6	57
80	Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with <i>de novo</i> three-vessel disease: final results of the SYNTAX II study. European Heart Journal, 2022, 43, 1307-1316.	2.2	54
81	Fate of stent-related side branches after coronary intervention in patients with in-stent restenosis. Journal of the American College of Cardiology, 2000, 36, 1549-1556.	2.8	53
82	Changes in thrombus composition and profilin-1 release in acute myocardial infarction. European Heart Journal, 2015, 36, 965-975.	2.2	52
83	Characterization of Plaque Prolapse After Drug-Eluting Stent Implantation in Diabetic Patients. Journal of the American College of Cardiology, 2006, 48, 1139-1145.	2.8	51
84	Anatomical and physiologic assessments in patients with small coronary artery disease: Final results of the Physiologic and Anatomical Evaluation Prior to and After Stent Implantation in Small Coronary Vessels (PHANTOM) trial. American Heart Journal, 2007, 153, 296.e1-296.e7.	2.7	51
85	Registro Español de Hemodinámica y CardiologÃa Intervencionista. XXIÂInforme Oficial deÂlaÂSección deĂHemodinámica y CardiologÃa Intervencionista deÂlaÂSociedad Española deÂCardiologÃa (1990-2011). Revista Espanola De Cardiologia, 2012, 65, 1106-1116.	1.2	50
86	807 C/T Polymorphism of the glycoprotein la gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. Blood Coagulation and Fibrinolysis, 2004, 15, 427-433.	1.0	49
87	Accurate Coronary Centerline Extraction, Caliber Estimation, and Catheter Detection in Angiographies. IEEE Transactions on Information Technology in Biomedicine, 2012, 16, 1332-1340.	3.2	49
88	Three-dimensional intravascular ultrasonic volumetric quantification of stent recoil and neointimal formation of two new generation tubular stents. American Journal of Cardiology, 2000, 85, 135-139.	1.6	46
89	Long-Term Clinical Benefit of Sirolimus-Eluting Stents in Patients With In-Stent Restenosis. Journal of the American College of Cardiology, 2008, 52, 1621-1627.	2.8	46
90	Vessel Shrinkage as a Sign of Atherosclerosis Progression in Type 2 Diabetes. Diabetes, 2009, 58, 209-214.	0.6	46

#	Article	IF	CITATIONS
91	Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial. EuroIntervention, 2016, 12, 1102-1107.	3.2	46
92	Percutaneous Mitral Valve Repair for Acute Mitral Regurgitation After an Acute Myocardial Infarction. Journal of the American College of Cardiology, 2015, 66, 91-92.	2.8	45
93	Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial). EuroIntervention, 2018, 13, 1561-1564.	3.2	45
94	Implementation of primary angioplasty in Europe: Stent for Life initiative progress report. EuroIntervention, 2012, 8, 35-42.	3.2	45
95	A Score to Assess Mortality After Percutaneous Mitral Valve Repair. Journal of the American College of Cardiology, 2022, 79, 562-573.	2.8	44
96	Intracoronary Administration of Allogeneic Adipose Tissue–Derived Mesenchymal Stem Cells Improves Myocardial Perfusion But Not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction. Journal of the American Heart Association, 2017, 6, .	3.7	43
97	Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function andÂOther Vascular Biomarkers. JACC: Cardiovascular Interventions, 2018, 11, 1576-1586.	2.9	43
98	Acute Coronary Syndrome Following Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e008620.	3.9	43
99	Comentarios a la guÃa de práctica clÃnica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevación del segmento ST. Revista Espanola De Cardiologia, 2013, 66, 5-11.	1.2	42
100	Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. EuroIntervention, 2011, 7, 977-984.	3.2	41
101	Endothelial and Smooth Muscle Cells Dysfunction Distal to Recanalized Chronic Total Coronary Occlusions and the Relationship With the Collateral Connection Grade. JACC: Cardiovascular Interventions, 2012, 5, 170-178.	2.9	39
102	Initial results and long-term clinical and angiographic outcome of coronary stenting in women. American Journal of Cardiology, 2000, 86, 1380-1383.	1.6	38
103	Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with Diabetes mellitus: a patient-level meta-analysis of randomized trials. Clinical Research in Cardiology, 2011, 100, 561-570.	3.3	38
104	Incidence and Potential Mechanism(s) ofÂPost-Procedural Rise of Cardiac BiomarkerÂin Patients With Coronary ArteryÂNarrowing After Implantation of anÂEverolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent. JACC: Cardiovascular Interventions, 2015, 8, 1053-1063.	2.9	36
105	Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension. Basic Research in Cardiology, 2016, 111, 49.	5.9	36
106	Early dysfunction and long-term improvement in endothelium-dependent vasodilation in the infarct-related artery after thrombolysis. Journal of the American College of Cardiology, 2002, 40, 257-265.	2.8	35
107	Effectiveness of percutaneous coronary interventions in nonagenarians. American Journal of Cardiology, 2004, 94, 1058-1060.	1.6	35
108	Lung Function Abnormalities are Highly Frequent in Patients with Heart Failure and Preserved Ejection Fraction. Heart Lung and Circulation, 2014, 23, 273-279.	0.4	35

#	Article	IF	CITATIONS
109	10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2021, 77, 1165-1178.	2.8	32
110	Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. EuroIntervention, 2016, 12, e550-e556.	3.2	32
111	LDL-cholesterol predicts negative coronary artery remodelling in diabetic patients: an intravascular ultrasound study. European Heart Journal, 2005, 26, 2307-2312.	2.2	31
112	Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2019, 74, 2572-2584.	2.8	31
113	Optimization in Stent Implantation by Manual Thrombus Aspiration in ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2014, 7, 294-300.	3.9	30
114	Infective endocarditis in patients with an implanted transcatheter aortic valve: Clinical characteristics and outcome of a new entity. Journal of Infection, 2015, 70, 565-576.	3.3	30
115	Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia. Resuscitation, 2017, 114, 141-145.	3.0	30
116	Benefits of chronic total coronary occlusion percutaneous intervention in patients with heart failure and reduced ejection fraction: insights from a cardiovascular magnetic resonance study. Journal of Cardiovascular Magnetic Resonance, 2016, 18, 78.	3.3	30
117	Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration. Journal of the American College of Cardiology, 2020, 75, 1386-1402.	2.8	30
118	Improvement of myocardial function and perfusion after successful percutaneous revascularization in patients with chronic total coronary occlusion. International Journal of Cardiology, 2013, 169, 147-152.	1.7	29
119	Long-Term Coronary Functional Assessment of the Infarct-Related ArteryÂTreated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents. JACC: Cardiovascular Interventions, 2018, 11, 1559-1571.	2.9	29
120	Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. European Heart Journal, 2018, 39, 3381-3389.	2.2	29
121	Quantitative measurements of in-stent restenosis: A comparison between quantitative coronary ultrasound and quantitative coronary angiography. Catheterization and Cardiovascular Interventions, 1999, 48, 133-142.	1.7	28
122	Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. Platelets, 2006, 17, 586-590.	2.3	26
123	Cardiogenic shock at admission in patients with multivessel disease and acute myocardial infarction treated with percutaneous coronary intervention: Related factors. International Journal of Cardiology, 2007, 123, 29-33.	1.7	26
124	Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis. JACC: Cardiovascular Interventions, 2017, 10, 1809-1815.	2.9	26
125	Impact of postâ€procedural minimal stent area on 2â€year clinical outcomes in the SYNTAX II trial. Catheterization and Cardiovascular Interventions, 2019, 93, E225-E234.	1.7	26
126	Molecular pathways involved in the cardioprotective effects of intravenous statin administration during ischemia. Basic Research in Cardiology, 2020, 115, 2.	5.9	26

#	Article	IF	CITATIONS
127	Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. European Heart Journal, 2022, 43, 1320-1330.	2.2	26
128	Methodological and clinical implications of the relocation of the minimal luminal diameter after intracoronary radiation therapy. Journal of the American College of Cardiology, 2000, 36, 1536-1541.	2.8	25
129	Intracoronary Brachytherapy After Stenting De Novo Lesions in Diabetic Patients. Journal of the American College of Cardiology, 2004, 44, 520-527.	2.8	25
130	Intravascular Ultrasound Characterization of the "Black Hole―Phenomenon After Drug-Eluting Stent Implantation. American Journal of Cardiology, 2006, 97, 203-206.	1.6	25
131	Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design. Cardiovascular Drugs and Therapy, 2008, 22, 313-320.	2.6	25
132	Sirolimusâ€eluting stents versus bareâ€metal stents in patients with inâ€stent restenosis: Results of a pooled analysis of two randomized studies. Catheterization and Cardiovascular Interventions, 2008, 72, 459-467.	1.7	25
133	Late Cerebrovascular Events Following Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 872-881.	2.9	25
134	Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study. EuroIntervention, 2016, 12, 482-489.	3.2	25
135	Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy. EuroIntervention, 2018, 14, e570-e579.	3.2	24
136	Repeat stenting for the prevention of the early lumen loss phenomenon in patients with in-stent restenosis. American Heart Journal, 2005, 149, e1-e8.	2.7	23
137	Qualitative and quantitative accuracy of ultrasound-based virtual histology for detection of necrotic core in human coronary arteries. International Journal of Cardiovascular Imaging, 2014, 30, 469-476.	1.5	23
138	1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 440-449.	2.9	23
139	Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. Journal of Invasive Cardiology, 2004, 16, 325-9.	0.4	23
140	In-hospital and Mid-term Predictors of Mortality After Transcatheter Aortic Valve Implantation: Data From the TAVI National Registry 2010-2011. Revista Espanola De Cardiologia (English Ed), 2013, 66, 949-958.	0.6	22
141	Five-Year Optical Coherence Tomography in Patients With ST-Segment–Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	22
142	IMPACT OF FINAL MINIMAL STENT AREA BY IVUS ON 3-YEAR OUTCOME AFTER PCI OF LEFT MAIN CORONARY ARTERY DISEASE: THE EXCEL TRIAL. Journal of the American College of Cardiology, 2017, 69, 963.	2.8	22
143	Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study. BMJ Open, 2018, 8, e020255.	1.9	22
144	Comentarios a la guÃa de práctica clÃnica de la ESC para el manejo del sÃndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Un informe del Grupo de Trabajo del Comité de GuÃas de Práctica ClÃnica de la Sociedad Española de CardiologÃa. Revista Espanola De Cardiologia, 2012, 65, 125-130.	1.2	21

#	Article	IF	CITATIONS
145	Comparison of Transfemoral Versus Transradial Secondary Access in Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e008609.	3.9	21
146	ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison. International Journal of Cardiology, 2016, 214, 483-484.	1.7	20
147	Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST–Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation. American Journal of Cardiology, 2017, 120, 1460-1466.	1.6	20
148	Clinical, Angiographic, and ProceduralÂCorrelates of VeryÂLateÂAbsorbÂScaffoldÂThrombosis. JACC: Cardiovascular Interventions, 2018, 11, 638-644.	2.9	20
149	Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention, 2020, 15, e1605-e1614.	3.2	20
150	Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial. EuroIntervention, 2013, 9, 328-335.	3.2	20
151	Therapeutic implications of in-stent restenosis located at the stent edge. Insights from the restenosis intra-stent balloon angioplasty versus elective stenting (RIBS) randomized trial. European Heart Journal, 2004, 25, 1829-1835.	2.2	19
152	Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: Design of the MUSICA-2 randomized trial. American Heart Journal, 2013, 166, 669-675.	2.7	19
153	Assessment of Plaque Composition by Intravascular Ultrasound and Near-Infrared Spectroscopy. Circulation Journal, 2014, 78, 1531-1539.	1.6	19
154	Prognosis of newâ€onset heart failure outpatients and collagen biomarkers. European Journal of Clinical Investigation, 2015, 45, 842-849.	3.4	19
155	Puncture Versus Surgical Cutdown Complications of Transfemoral Aortic Valve Implantation (from) Tj ETQq1 1 0.	784314 rg 1.6	gBT_/Overloc
156	Assessment of potential relationship between wall shear stress and arterial wall response after bare metal stent and sirolimus-eluting stent implantation in patients with diabetes mellitus. International Journal of Cardiovascular Imaging, 2008, 24, 357-364.	1.5	18
157	Zotarolimus for the treatment of coronary artery disease: pathophysiology, DES design, clinical evaluation and future perspective. Expert Opinion on Pharmacotherapy, 2009, 10, 1047-1058.	1.8	18
158	Determinantes del éxito de la revascularización de las oclusiones coronarias crónicas: estudio mediante tomografÃa computarizada con multidetectores. Revista Espanola De Cardiologia, 2012, 65, 334-340.	1.2	18
159	Three-dimensional printing of an aortic model for transcatheter aortic valve implantation: possible clinical applications. International Journal of Cardiovascular Imaging, 2017, 33, 283-285.	1.5	18
160	The 2011-2012 pilot European Society of Cardiology Sentinel Registry of Transcatheter Aortic Valve Implantation: 12-month clinical outcomes. EuroIntervention, 2016, 12, 79-87.	3.2	18
161	Comparison of brachytherapy strategies based on dose-volume histograms derived from quantitative intravascular ultrasound. Cardiovascular Radiation Medicine, 1999, 1, 115-124.	0.6	17
162	Pressure wire kinking, entanglement, and entrapment during intravascular ultrasound studies: A potentially dangerous complication. Catheterization and Cardiovascular Interventions, 2000, 50, 221-225.	1.7	17

#	Article	IF	CITATIONS
163	Relocation of minimal luminal diameter after bare metal and drug-eluting stent implantation: Incidence and impact on angiographic late loss. Catheterization and Cardiovascular Interventions, 2007, 69, 181-188.	1.7	17
164	Cost-effectiveness of a European ST-segment elevation myocardial infarction network: results from the CatalanCodi Infartnetwork. BMJ Open, 2015, 5, e009148.	1.9	17
165	Everolimus-eluting stent versus bare-metal stent in elderly (≥75years) versus non-elderly (<75years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the examination trial. International Journal of Cardiology, 2015, 179, 73-78.	1.7	17
166	Comparison of the Frequency of Thrombocytopenia After Transfemoral Transcatheter Aortic Valve Implantation Between Balloon-Expandable and Self-Expanding Valves. American Journal of Cardiology, 2019, 123, 1120-1126.	1.6	17
167	Outcomes of Nonagenarians With ST Elevation Myocardial Infarction. American Journal of Cardiology, 2020, 125, 11-18.	1.6	17
168	Myocardial Injury in COVID-19 Patients: Association with Inflammation, Coagulopathy and In-Hospital Prognosis. Journal of Clinical Medicine, 2021, 10, 2096.	2.4	17
169	First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial. EuroIntervention, 2018, 13, 2026-2035.	3.2	17
170	Reproducibility of qualitative assessment of stent struts coverage by optical coherence tomography. International Journal of Cardiovascular Imaging, 2013, 29, 5-11.	1.5	16
171	ST-Segment Elevation Myocardial Infarction. Circulation Journal, 2015, 79, 263-270.	1.6	16
172	Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions. JACC: Cardiovascular Interventions, 2017, 10, 560-568.	2.9	16
173	Effect of pulmonary artery denervation in postcapillary pulmonary hypertension: results of a randomized controlled translational study. Basic Research in Cardiology, 2019, 114, 5.	5.9	16
174	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. EuroIntervention, 2019, 15, e539-e546.	3.2	16
175	Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial. EuroIntervention, 2020, 16, e913-e921.	3.2	16
176	Acute and Chronic Effects of COVID-19 on the Cardiovascular System. Journal of Cardiovascular Development and Disease, 2021, 8, 128.	1.6	16
177	Randomized Comparison Between Polymer-Free Versus Polymer-Based Paclitaxel-Eluting Stent. Circulation: Cardiovascular Interventions, 2014, 7, 312-321.	3.9	15
178	Impact of overlapping on 1â€year clinical outcomes in patients undergoing everolimusâ€eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOSTâ€EU registry. Catheterization and Cardiovascular Interventions, 2017, 89, 812-818.	1.7	15
179	Impact of revascularization versus medical therapy alone for chronic total occlusion management in older patients. Catheterization and Cardiovascular Interventions, 2019, 94, 527-535.	1.7	15
180	Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial). EuroIntervention, 2018, 14, e1224-e1226.	3.2	14

#	Article	IF	CITATIONS
181	Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: a pooled analysis of individual patient data. EuroIntervention, 2020, 15, 1451-1457.	3.2	14
182	Acute Absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent?. EuroIntervention, 2014, 10, 600-600.	3.2	14
183	Primary percutaneous coronary intervention: models of intervention in Spain. EuroIntervention, 2012, 8, P90-P93.	3.2	14
184	Pathological Effects of Pulmonary Vein beta-Radiation in a Swine Model. Journal of Cardiovascular Electrophysiology, 2006, 17, 662-669.	1.7	13
185	First experience of a bioresorbable vascular scaffold implantation in left main stenosis. International Journal of Cardiology, 2013, 168, 1566-1568.	1.7	13
186	Eficacia y seguridad a mÃ _i s de 10 años de la ablación septal percutánea en la miocardiopatÃa hipertrófica obstructiva. Revista Espanola De Cardiologia, 2014, 67, 353-358.	1.2	13
187	Sex differences in angiotensin II responses contribute to a differential regulation of cox-mediated vascular dysfunction during aging. Experimental Gerontology, 2016, 85, 71-80.	2.8	13
188	Safety of glycoprotein IIb/IIIa inhibitors in patients under therapeutic hypothermia admitted for an acute coronary syndrome. Resuscitation, 2016, 106, 108-112.	3.0	13
189	Levosimendan as an adjunctive therapy to MitraClip implantation in patients with severe mitral regurgitation and left ventricular dysfunction. International Journal of Cardiology, 2016, 202, 517-518.	1.7	13
190	Usefulness of Drug-Eluting Balloons for Bare-Metal and Drug-Eluting In-Stent Restenosis (from the) Tj ETQq0 0 0	rgBT /Ove 1.6	erlock 10 Tf 50
191	Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation. JACC: Cardiovascular Interventions, 2017, 10, 1867-1877.	2.9	13
192	Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study. EuroIntervention, 2020, 15, 1436-1443.	3.2	13
193	Predictors and implications of residual plaque burden after coronary stenting: An intravascular ultrasound study. American Heart Journal, 2003, 145, 254-261.	2.7	12
194	Effectiveness and Safety Beyond 10 Years of Percutaneous Transluminal Septal Ablation in Hypertrophic Obstructive Cardiomyopathy. Revista Espanola De Cardiologia (English Ed), 2014, 67, 353-358.	0.6	12
195	Comentarios a la guÃa ESC 2017 sobre el tratamiento del infarto agudo de miocardio en pacientes con elevación del segmento ST. Revista Espanola De Cardiologia, 2017, 70, 1039-1045.	1.2	12
196	Intravenous Statin Administration During Ischemia Exerts Cardioprotective Effects. Journal of the American College of Cardiology, 2019, 74, 475-477.	2.8	12
197	Recurrent atherosclerosis complications as a mechanism for stent failure. Hellenic Journal of Cardiology, 2020, 61, 9-14.	1.0	12
198	Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: A structured summary of a study protocol. PLoS ONE, 2021, 16, e0255263.	2.5	12

#	Article	IF	CITATIONS
199	Quality difference of neointima following the implantation of everolimus-eluting bioresorbable scaffolds and metallic stents in patients with ST-elevation myocardial infarction: quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography in the TROFI II trial. EuroIntervention, 2018, 14, 678-685.	3.2	12
200	A randomised comparison between everolimus-eluting stent and sirolimus-eluting stent in chronic coronary total occlusions. Rationale and design of the CIBELES (non-acute Coronary occlusion) Tj ETQq0 0 0 rgBT	/@verlock	10 Tf 50 69
201	Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials. EuroIntervention, 2015, 11, 391-398.	3.2	12
202	Influence of the CD14 C260T Promoter Polymorphism on C-Reactive Protein Levels in Patients With Coronary Artery Disease. American Journal of Cardiology, 2006, 98, 1182-1184.	1.6	11
203	Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization. Vascular Health and Risk Management, 2009, 5, 101.	2.3	11
204	Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2013, 168, 2632-2636.	1.7	11
205	Impact of the "ACT NOW. SAVE A LIFE―public awareness campaign on the performance of a European STEMI network. International Journal of Cardiology, 2015, 197, 110-112.	1.7	11
206	Influencia del sexo en los resultados clÃnicos de los stents liberadores de everolimus en comparación con los stents metálicos sin recubrimiento en el infarto agudo de miocardio con elevación del segmento ST. Perspectivas del ensayo EXAMINATION. Revista Espanola De Cardiologia, 2015, 68, 382-389.	1.2	11
207	Latest STEMI treatment: a focus on current and upcoming devices. Expert Review of Medical Devices, 2018, 15, 807-817.	2.8	11
208	Thrombocytopenia after transcatheter aortic valve implantation. A comparison between balloonâ€expandable and selfâ€expanding valves. Catheterization and Cardiovascular Interventions, 2019, 93, 1344-1351.	1.7	11
209	Sex-based differences in chronic total occlusion management and long-term clinical outcomes. International Journal of Cardiology, 2020, 319, 46-51.	1.7	11
210	Kv1.3 blockade inhibits proliferation of vascular smooth muscle cells in vitro and intimal hyperplasia in vivo. Translational Research, 2020, 224, 40-54.	5.0	11
211	Sexâ€gender disparities in nonagenarians with acute coronary syndrome. Clinical Cardiology, 2021, 44, 371-378.	1.8	11
212	Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in patients with) Tj ETQqO 0 0 rgBT ((English Ed), 2022, 75, 515-522.	Overlock 1 0.6	0 Tf 50 227 11
213	A randomised trial of paclitaxel-eluting balloon after bare metal stent implantation vs. bare metal stent in ST-elevation myocardial infarction (the PEBSI study). EuroIntervention, 2017, 12, 1587-1594.	3.2	11
214	Low Dose of Direct Oral Anticoagulants after Left Atrial Appendage Occlusion. Journal of Cardiovascular Development and Disease, 2021, 8, 142.	1.6	11
215	Predictive factors and long-term evolution of early endothelial dysfunction after cardiac transplantation. Journal of Heart and Lung Transplantation, 2000, 19, 453-461.	0.6	10
216	Recanalized Thrombus Treated With Bioresorbable Vascular Scaffold. JACC: Cardiovascular Interventions, 2014, 7, 1453-1455.	2.9	10

#	Article	IF	CITATIONS
217	Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION) Tj ETQq1 1 Cardiology, 2018, 121, 1039-1045.	D.784314 1.6	rgBT /Overio
218	Falsos positivos en la activación por IAMCEST en una red regional: análisis integral e impacto clÃnico. Resultados del registro Codi Infart de Cataluña. Revista Espanola De Cardiologia, 2018, 71, 243-249.	1.2	10
219	Impact of PSP Technique on Clinical Outcomes Following Bioresorbable Scaffolds Implantation. Journal of Clinical Medicine, 2018, 7, 27.	2.4	10
220	MAGnesiumâ€based bioresorbable scaffold and vasomotor function in patients with acute ST segment elevation myocardial infarction: The MAGSTEMI trial: Rationale and design. Catheterization and Cardiovascular Interventions, 2019, 93, 64-70.	1.7	10
221	Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale and design of the BIOVASC trial. American Heart Journal, 2020, 227, 111-117.	2.7	10
222	Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks. Postepy W Kardiologii Interwencyjnej, 2015, 3, 161-169.	0.2	9
223	Overtime evaluation of the vascular HEALing process after everolimus-eluting stent implantation by optical coherence tomography. The HEAL-EES study. Cardiovascular Revascularization Medicine, 2016, 17, 241-247.	0.8	9
224	Costâ€effectiveness of percutaneous coronary intervention with cobaltâ€chromium everolimus eluting stents versus bare metal stents: Results from a patient level metaâ€analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2017, 89, 994-1002.	1.7	9
225	False Positive STEMI Activations in a Regional Network: Comprehensive Analysis and Clinical Impact. Results From the Catalonian Codi Infart Network. Revista Espanola De Cardiologia (English Ed), 2018, 71, 243-249.	0.6	9
226	Pulmonary function predicts mortality and hospitalizations in outpatients with heart failure and preserved ejection fraction. Respiratory Medicine, 2018, 134, 124-129.	2.9	9
227	Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy. Journal of Clinical Medicine, 2021, 10, 2276.	2.4	9
228	Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry. EuroIntervention, 2017, 13, e1104-e1111.	3.2	9
229	Endothelial progenitor cell capturing stent and short dual antiplatelet therapy in patients on chronic anti-vitamin k regimen undergoing percutaneous coronary interventions: long-term outcomes of a single centre registry. EuroIntervention, 2011, 6, 831-837.	3.2	9
230	The SYNERGY II Everolimus elutiNg stent In patients Older than 75 years undergoing coronary Revascularisation associated with a short dual antiplatelet therapy (SENIOR) trial: rationale and design of a large-scale randomised multicentre study. EuroIntervention, 2017, 12, 1614-1622.	3.2	9
231	Magnesium-based resorbable scaffold vs permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: 3-year results of the MAGSTEMI randomised controlled trial. EuroIntervention, 2022, 18, e389-e396.	3.2	9
232	Angiographic and 3D intravascular ultrasound assessment of overlapping bare metal stent and three different formulations of drug-eluting stents in patients with diabetes mellitus. International Journal of Cardiovascular Imaging, 2008, 24, 125-132.	1.5	8
233	Rationale and study design of the <scp>RESERVOIR</scp> trial: A randomized trial comparing reservoirâ€based polymerâ€free amphilimusâ€eluting stents versus everolimusâ€eluting stents with durable polymer in patients with diabetes mellitus. Catheterization and Cardiovascular Interventions, 2015, 85, F116-22	1.7	8
234	Frequency and predictors of thrombus inside the guiding catheter during interventional procedures: an optical coherence tomography study. International Journal of Cardiovascular Imaging, 2015, 31, 239-246.	1.5	8

#	Article	IF	CITATIONS
235	Bioresorbable vascular scaffolds technology: current use and future developments. Medical Devices: Evidence and Research, 2016, Volume 9, 185-198.	0.8	8
236	Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the <scp>E</scp> uropean <scp>M</scp> ulticentre <scp>GHOST</scp> â€ <scp>EU</scp> <scp>R</scp> egistry. Catheterization and Cardiovascular Interventions, 2018, 91, 444-453.	1.7	8
237	Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the five-year follow-up of the EXAMINATION trial. EuroIntervention, 2017, 13, e557-e563.	3.2	8
238	Intracoronary brachytherapy following drug-eluting stent failure It's still not time to hang up the spikes!. Cardiovascular Radiation Medicine, 2003, 4, 171-175.	0.6	7
239	Isolated right ventricular infarction presenting with anterior ST-segment elevation: A case for careful assessment of right ventricular branch occlusion. Revista Portuguesa De Cardiologia, 2012, 31, 301-304.	0.5	7
240	Percutaneous transcatheter aortic valve implantation: present and future perspective. Expert Review of Medical Devices, 2013, 10, 185-199.	2.8	7
241	«No es paÃs para viejos» con infarto agudo de miocardio y elevación del segmentoÂST. Revista Espanola De Cardiologia, 2017, 70, 70-71.	1.2	7
242	Three―and 6â€month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drugâ€eluting stent: The ANCHOR study. Catheterization and Cardiovascular Interventions, 2018, 91, 435-443.	1.7	7
243	Cell-free DNA and Microvascular Damage in ST-segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Revista Espanola De Cardiologia (English Ed), 2019, 72, 317-323.	0.6	7
244	Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design. American Heart Journal, 2020, 222, 174-182.	2.7	7
245	Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program. Journal of Clinical Medicine, 2021, 10, 4252.	2.4	7
246	Spontaneous coronary artery dissection: Not so infrequent to be ignored. Medicina ClÃnica, 2019, 153, 245-249.	0.6	7
247	Spain: coronary and structural heart interventions from 2010 to 2015. EuroIntervention, 2017, 13, Z64-Z69.	3.2	7
248	Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. EuroIntervention, 2018, 13, 1939-1945.	3.2	7
249	Coronary vasomotor function and myocardial flow with bioresorbable vascular scaffolds or everolimus-eluting metallic stents: a randomised trial. EuroIntervention, 2020, 16, e155-e163.	3.2	7
250	Guidewire-induced coronary pseudostenosis as a source of error during physiological guidance of stent deployment. Catheterization and Cardiovascular Interventions, 2000, 51, 91-94.	1.7	6
251	Acute stent thrombosis after early withdrawal of platelet glycoprotein IIb/IIIa antagonists: Potential rebound prothrombotic effect?. Catheterization and Cardiovascular Interventions, 2003, 58, 481-484.	1.7	6
252	Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: Need to assess aspirin resistance?. Catheterization and Cardiovascular Interventions, 2004, 62, 39-42.	1.7	6

#	Article	IF	CITATIONS
253	STEMI Interventions. Interventional Cardiology Clinics, 2012, 1, 559-565.	0.4	6
254	Oneâ€year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent. Catheterization and Cardiovascular Interventions, 2013, 82, E428-36.	1.7	6
255	Impact of therapeutic hypothermia on coronary flow. International Journal of Cardiology, 2014, 172, 228-229.	1.7	6
256	Comments on the 2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-segment Elevation. Revista Espanola De Cardiologia (English Ed), 2017, 70, 1039-1045.	0.6	6
257	TIcaGrEloR and Absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization (TIGERâ€BVS trial): Rationale and study design. Catheterization and Cardiovascular Interventions, 2018, 91, 1-6.	1.7	6
258	Procedural, Functional and Prognostic Outcomes Following Recanalization of Coronary Chronic Total Occlusions. Results of the Iberian Registry. Revista Espanola De Cardiologia (English Ed), 2019, 72, 373-382.	0.6	6
259	Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?. Circulation: Cardiovascular Interventions, 2019, 12, e007705.	3.9	6
260	Minimally Invasive Transradial Percutaneous Closure of an Aortic Paravalvular Leak After Transcatheter Aortic Valve Replacement. Canadian Journal of Cardiology, 2019, 35, 941.e1-941.e2.	1.7	6
261	Moderate Hypothermia Modifies Coronary Hemodynamics and Endotheliumâ€Dependent Vasodilation in a Porcine Model of Temperature Management. Journal of the American Heart Association, 2020, 9, e014035.	3.7	6
262	Survival benefit of revascularization versus optimal medical therapy alone for chronic total occlusion management in patients with diabetes. Catheterization and Cardiovascular Interventions, 2021, 97, 376-383.	1.7	6
263	Predicting 2â€year allâ€cause mortality after contemporary <scp>PCI</scp> : Updating the logistic clinical <scp>SYNTAX</scp> score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	1.7	6
264	Outcomes of Nonagenarians With Acute Coronary Syndrome. Journal of the American Medical Directors Association, 2022, 23, 81-86.e4.	2.5	6
265	EcocardiografÃa transesófagica mÃnimamente invasiva conÂmicrosonda deÂúltima generación para el cierre percutáneo deÂlaÂorejuela izquierda. Experiencia inicial. Revista Espanola De Cardiologia, 2019, 72, 511-512.	1.2	6
266	A randomised controlled trial of the sirolimus-eluting biodegradable polymer ultra-thin Supraflex stent versus the everolimus-eluting biodegradable polymer SYNERGY stent for three-vessel coronary artery disease: rationale and design of the Multivessel TALENT trial. EuroIntervention, 2020, 16, e997-e1004.	3.2	6
267	Coronary Microvascular Angina: A State-of-the-Art Review. Frontiers in Cardiovascular Medicine, 2022, 9, 800918.	2.4	6
268	The ESSEX (European Scimed Stent Experience) study. Catheterization and Cardiovascular Interventions, 2000, 50, 419-425.	1.7	5
269	Spanish Cardiac Catheterization and Coronary Intervention Registry. 20th Official Report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2010). Revista Espanola De Cardiologia (English Ed), 2011, 64, 1012-1022.	0.6	5
270	Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction. American Heart Journal, 2013, 166, 119-126.e1.	2.7	5

#	Article	IF	CITATIONS
271	RAndomized Comparison of raDIal vs. femorAL Access for Routine Catheterization of Heart Transplant Patients (RADIAL – Heart Transplant Study). Transplantation Proceedings, 2014, 46, 3262-3267.	0.6	5
272	Radial Versus Femoral Access for Angioplasty of ST-segment Elevation Acute Myocardial Infarction With Second-generation Drug-eluting Stents. Revista Espanola De Cardiologia (English Ed), 2015, 68, 47-53.	0.6	5
273	Endothelial function impairment in STEMI patients with out-of-hospital cardiac arrest under therapeutic hypothermia treatment. International Journal of Cardiology, 2017, 232, 70-75.	1.7	5
274	Minimally-invasive Transesophageal Echocardiography for Left Atrial Appendage Occlusion With a Latest-generation Microprobe. Initial Experience. Revista Espanola De Cardiologia (English Ed), 2019, 72, 511-512.	0.6	5
275	Longâ€ŧerm impact of diabetes in patients with STâ€segment elevation myocardial infarction: Insights from the EXAMINATION randomized trial. Catheterization and Cardiovascular Interventions, 2019, 94, 917-925.	1.7	5
276	Safety and outcomes of MitraClip implantation in functional mitral regurgitation according to degree of left ventricular dysfunction. Revista Espanola De Cardiologia (English Ed), 2020, 73, 530-535.	0.6	5
277	New Interventional Therapies beyond Stenting to Treat ST-Segment Elevation Acute Myocardial Infarction. Journal of Cardiovascular Development and Disease, 2021, 8, 100.	1.6	5
278	The Resorbable Magnesium Scaffold Magmaris in Acute Coronary Syndrome: An Appraisal of Evidence and User Group Guidance. Cardiovascular Revascularization Medicine, 2022, 39, 106-113.	0.8	5
279	Does manual thrombus aspiration help optimize stent implantation in ST-segment elevation myocardial infarction?. World Journal of Cardiology, 2014, 6, 1030.	1.5	5
280	Linking In Vitro Models of Endothelial Dysfunction with Cell Senescence. Life, 2021, 11, 1323.	2.4	5
281	A case-control, multicentre study of consecutive patients with COVID-19 and acute (myo)pericarditis: incidence, risk factors, clinical characteristics and outcomes. Emergency Medicine Journal, 2022, 39, 402-410.	1.0	5
282	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. Revista Espanola De Cardiologia (English Ed), 2022, , .	0.6	5
283	The role of intravascular ultrasound imaging in vascular brachytherapy. International Journal of Cardiovascular Interventions, 2000, 3, 3-12.	0.5	4
284	Primary percutaneous coronary intervention of an anomalous right coronary artery originating from the left sinus of valsalva. Acute Cardiac Care, 2006, 8, 229-232.	0.2	4
285	Update on Interventional Cardiology. Revista Espanola De Cardiologia (English Ed), 2013, 66, 282-289.	0.6	4
286	Can new generation P2Y12 inhibitors play a role in microvascular obstruction in STEMI?. International Journal of Cardiology, 2016, 223, 226-227.	1.7	4
287	Minimally Invasive Transradial Percutaneous Closure of Aortic Paravalvular Leaks: Following the Steps of Percutaneous Coronary Intervention. Canadian Journal of Cardiology, 2016, 32, 1575.e17-1575.e19.	1.7	4
288	Thrombectomy and Stroke. Journal of the American College of Cardiology, 2018, 72, 1597-1599.	2.8	4

#	Article	IF	CITATIONS
289	Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trial. American Heart Journal, 2018, 204, 205-209.	2.7	4
290	Multivessel spontaneous coronary artery dissection involving the left main coronary artery: a case report. European Heart Journal - Case Reports, 2019, 3, yty168.	0.6	4
291	Transcatheter Mitral Repair for Functional Mitral Regurgitation According to Left Ventricular Function: A Real-Life Propensity-Score Matched Study. Journal of Clinical Medicine, 2020, 9, 1792.	2.4	4
292	Antithrombotic regimens for percutaneous coronary intervention of the left main coronary artery: The EXCEL trial. Catheterization and Cardiovascular Interventions, 2021, 97, 766-773.	1.7	4
293	Impact of pre-angioplasty antithrombotic therapy administration on coronary reperfusion in ST-segment elevation myocardial infarction: Does time matter?. International Journal of Cardiology, 2021, 325, 9-15.	1.7	4
294	Coronary endothelial and microvascular function distal to polymer-free and endothelial cell-capturing drug-eluting stents. The randomized FUNCOMBO trial. Revista Espanola De Cardiologia (English Ed), 2021, 74, 1013-1022.	0.6	4
295	Thin- versus thick-strut polymer-free biolimus-eluting stents: the BioFreedom QCA randomised trial. EuroIntervention, 2021, 17, 233-239.	3.2	4
296	Restenosis patterns after bioresorbable vascular scaffold implantation: Angiographic substudy of the <scp>GHOST</scp> â€ <scp>EU</scp> registry. Catheterization and Cardiovascular Interventions, 2018, 92, 276-282.	1.7	4
297	Drugâ€Eluting or Bareâ€Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. Journal of the American Heart Association, 2021, 10, e018828.	3.7	4
298	The impact of the COVID-19 pandemic upon patients, staff, and on the future practices of percutaneous coronary intervention. European Heart Journal Supplements, 2020, 22, P13-P18.	0.1	4
299	Coronary Endotheliumâ€Dependent Vasomotor Function After Drugâ€Eluting Stent and Bioresorbable Scaffold Implantation. Journal of the American Heart Association, 2021, 10, e022123.	3.7	4
300	MitraClip® Repair in Cardiogenic Shock Due to Acute Mitral Regurgitation: From Near-Death to Walking. Journal of Heart Valve Disease, 2018, 27, 114-116.	0.5	4
301	Circulating miRNA Fingerprint and Endothelial Function in Myocardial Infarction: Comparison at Acute Event and One-Year Follow-Up. Cells, 2022, 11, 1823.	4.1	4
302	Intracoronary Ultrasound Longitudinal Reconstruction of a Postangioplasty Coronary Artery Dissection. Circulation, 1999, 99, E17.	1.6	3
303	Intravascular Ultrasound in Patients with Challenging In-Stent Restenosis: Importance of Precise Stent Visualization. Journal of Interventional Cardiology, 2006, 19, 153-159.	1.2	3
304	Spanish Cardiac Catheterization and Coronary Intervention Registry. 21st Official Report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2011). Revista Espanola De Cardiologia (English Ed), 2012, 65, 1106-1116.	0.6	3
305	Techniques and material used in the percutaneous treatment of chronic coronary occlusions. Data from the CIBELES study. Revista Portuguesa De Cardiologia, 2013, 32, 593-599.	0.5	3
306	Predictores de mortalidad hospitalaria y a medio plazo tras elÂreemplazo valvular aórtico transcatéter: datos delÂregistro nacional TAVI 2010-2011. Cirugia Cardiovascular, 2013, 20, 174-183.	0.1	3

#	Article	IF	CITATIONS
307	Sex-related Impact on Clinical Outcome of Everolimus-eluting Versus Bare-metal Stents in ST-segment Myocardial Infarction. Insights From the EXAMINATION Trial. Revista Espanola De Cardiologia (English) Tj ETQq1	1 @ 7 8431	4 s gBT /Over
308	The incidence and relevance of site-reported vs. patient-reported angina: insights from the ABSORB II randomized trial comparing Absorb everolimus-eluting bioresorbable scaffold with XIENCE everolimus-eluting metallic stent. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 2, 108-116.	4.0	3
309	Percutaneous Treatment of ExtremelyÂSmall Coronary Vessels. JACC: Cardiovascular Interventions, 2017, 10, 1389-1391.	2.9	3
310	In Vivo Evaluation of the Synergic Effect of Metformin and mTOR Inhibitors on the Endothelial Healing of Drug-eluting Stents in Diabetic Patients. Revista Espanola De Cardiologia (English Ed), 2018, 71, 917-925.	0.6	3
311	Análisis morfológico y funcional de la arteria descendente anterior de pacientes con sÃndrome de tako-tsubo. Revista Espanola De Cardiologia, 2018, 71, 986-988.	1.2	3
312	Angina e isquemia a los 2 años con armazón vascular bioabsorbible y stents farmacoactivos metálicos. Estudio ESTROFA Isquemia AVB-SFAm. Revista Espanola De Cardiologia, 2018, 71, 327-334.	1.2	3
313	Reparación percutánea de la válvula tricúspide con el sistema MitraClip: primer implante en España. Revista Espanola De Cardiologia, 2018, 71, 976-977.	1.2	3
314	Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. PLoS ONE, 2018, 13, e0201985.	2.5	3
315	Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial. Value in Health, 2019, 22, 1355-1361.	0.3	3
316	Endothelial shear stress and vascular remodeling in bioresorbable scaffold and metallic stent. Atherosclerosis, 2020, 312, 79-89.	0.8	3
317	Delayed Mitral Leaflet Perforation in a Tethered Valve After MitraClip XTR Implantation. JACC: Cardiovascular Interventions, 2020, 13, 2438-2439.	2.9	3
318	Comparison of clinical outcomes in STEMI patients treated with primary PCI according to day-time of medical attention and its relationship with circadian pattern. International Journal of Cardiology, 2020, 305, 35-41.	1.7	3
319	Intrapatient Randomization to Study Strut Coverage in Polymer-Free Versus Biodegradable-Polymer Sirolimus-Eluting Stent Implantations. JACC: Cardiovascular Interventions, 2020, 13, 899-900.	2.9	3
320	Prognosis of Patients With Reduced Left Ventricular Ejection Fraction and Chronic Total Occlusion According to Treatment Applied. Cardiovascular Revascularization Medicine, 2021, 27, 22-27.	0.8	3
321	Impact of chronic kidney disease in chronic total occlusion management and clinical outcomes. Cardiovascular Revascularization Medicine, 2021, , .	0.8	3
322	Coronary bifurcation stenting using dedicated bifurcation stents. Catheterization and Cardiovascular Interventions, 2000, 49, 105-111.	1.7	3
323	Selective use of contemporary drug-eluting stents in primary angioplasty for ST-elevation myocardial infarction: pooled analysis of COMFORTABLE AMI and EXAMINATION. EuroIntervention, 2017, 12, 1577-1586.	3.2	3
324	Association between coronary atherosclerosis progression and in-stent neoatherosclerosis in patients with ST-elevation myocardial infarction at five-year follow-up. EuroIntervention, 2018, 14, 206-214.	3.2	3

#	Article	IF	CITATIONS
325	Stent thrombosis in the era of drug-eluting stents. , 2008, , 211-219.		3
326	Assessment of Dynamic Coronary Plaque Changes and the Clinical Consequences in Type-II Diabetic Patients: a Serial Intracoronary Ultrasound Study. Revista Espanola De Cardiologia (English Ed), 2011, 64, 557-563.	0.6	2
327	Endothelial Function in Coronary Chronic Total Occlusions. Journal of the American College of Cardiology, 2012, 60, 871-872.	2.8	2
328	Techniques and material used in the percutaneous treatment of chronic coronary occlusions. Data from the CIBELES study. Revista Portuguesa De Cardiologia (English Edition), 2013, 32, 593-599.	0.2	2
329	TCT-419 Usefulness of a scoring system for predicting adverse cardiovascular events in patients undergoing everolimus-eluting bioresorbable scaffolds implantation: the PSP score. Journal of the American College of Cardiology, 2016, 68, B169-B170.	2.8	2
330	A longer look at trial evidence of bioresorbable vascular scaffolds. Heart, 2017, 103, 1061-1062.	2.9	2
331	Functional and Morphological Assessment of Left Anterior Descending Artery in Patients With Tako-tsubo Syndrome. Revista Espanola De Cardiologia (English Ed), 2018, 71, 986-988.	0.6	2
332	Evaluación del efecto sinérgico de la metformina y los inhibidores mTOR sobre la endotelización de los stents farmacoactivos en pacientes diabéticos. Revista Espanola De Cardiologia, 2018, 71, 917-925.	1.2	2
333	Percutaneous coronary intervention due to chronic total occlusion in the left main coronary artery after bypass grafting: A feasible option in selected cases. Revista Portuguesa De Cardiologia, 2018, 37, 865.e1-865.e4.	0.5	2
334	The Long-Term Impact of Post-Procedural Asymmetry and Eccentricity of Bioresorbable Everolimus-Eluting ScaffoldÂand Metallic Everolimus-Eluting Stent onÂClinical Outcomes inÂtheÂABSORB II Trial. JACC: Cardiovascular Interventions, 2018, 11, 1013-1015.	2.9	2
335	Eventos trombóticos y hemorrágicos después de una intervención coronaria percutánea tras parada cardiaca extrahospitalaria con y sin hipotermia terapéutica. Revista Espanola De Cardiologia, 2019, 72, 433-435.	1.2	2
336	Effect of sildenafil on right ventricular performance in an experimental large-animal model of postcapillary pulmonary hypertension. Translational Research, 2021, 228, 64-75.	5.0	2
337	Longitudinal Neointimal Distribution Pattern After Everolimus-Eluting Stent Implantation: Insights From Optical Coherence Tomography Study. Cardiovascular Revascularization Medicine, 2021, 26, 17-23.	0.8	2
338	Función endotelial y microvascular distal a stents farmacoactivos sin polÃmero y captadores de células endoteliales. Estudio aleatorizado FUNCOMBO. Revista Espanola De Cardiologia, 2021, 74, 1014-1023.	1.2	2
339	Drug-Coated Balloon for Diabetic Patients With Small Coronary Vessels. JACC: Cardiovascular Interventions, 2021, 14, 1799-1800.	2.9	2
340	Amplatzer Vascular Plug III and Interclip Mitral Regurgitation. JACC: Cardiovascular Interventions, 2021, 14, e9-e10.	2.9	2
341	Descifrando la fisiopatologÃa de la disección coronaria espontánea. Revista Espanola De Cardiologia, 2019, 72, 604-605.	1.2	2
342	How should I treat subacute stent thrombosis in the context of brain haemorrhage with abciximab?. EuroIntervention, 2015, 10, e1-e6.	3.2	2

#	Article	IF	CITATIONS
343	The future of vascular restoration therapy. EuroIntervention, 2018, 14, e976-e979.	3.2	2
344	Drug-eluting stents and acute myocardial infarction: A lethal combination or friends?. World Journal of Cardiology, 2014, 6, 929.	1.5	2
345	Paravalvular Leak Correction: Searching for a Balance Between Surgical and Percutaneous Techniques. Revista Espanola De Cardiologia (English Ed), 2018, 71, 679-681.	0.6	2
346	Spanish Cardiac Catheterization and Coronary Intervention Registry. 30th Official Report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2020) in the year of the COVID-19 pandemic. Revista Espanola De Cardiologia (English Ed), 2021, 74, 1095-1105.	0.6	2
347	Transcatheter aortic valve implantation in patients with left main percutaneous coronary intervention. Journal of Heart Valve Disease, 2013, 22, 874-7.	0.5	2
348	Bioresorbable vascular scaffolds in clinical practice: state-of-the-art. Panminerva Medica, 2016, 58, 130-42.	0.8	2
349	Initial Results of Combined MitraClipÃ,® Implantation and Left Atrial Appendage Occlusion. Journal of Heart Valve Disease, 2017, 26, 169-174.	0.5	2
350	Spontaneous Coronary Artery Dissection: Rediscovering an old cause of myocardial infarction. Journal of Cardiothoracic and Vascular Anesthesia, 2022, , .	1.3	2
351	Sirolimus Versus Paclitaxel. JACC: Cardiovascular Interventions, 2022, 15, 780-782.	2.9	2
352	Stent implantation through a self-expanding stent. International Journal of Cardiovascular Interventions, 1998, 1, 45-48.	0.5	1
353	Percutaneous coronary revascularization in diabetics: from balloon angioplasty to drug-eluting stents. Expert Review of Cardiovascular Therapy, 2005, 3, 635-646.	1.5	1
354	Sirolimus-Eluting Stents vs Brachytherapy for Restenosis. JAMA - Journal of the American Medical Association, 2006, 296, 1837.	7.4	1
355	Drug eluting stent implantation in patients requiring concomitant vitamin K antagonist therapy. One-year outcome of the worldwide e-SELECT registry. International Journal of Cardiology, 2013, 168, 2522-2527.	1.7	1
356	Distal side-branch technique: A new use for the Tornus® Catheter. Cardiovascular Revascularization Medicine, 2014, 15, 97-99.	0.8	1
357	Edge Vascular Response After Polymer-Free vs. Polymer-Based Paclitaxel-Eluting Stent Implantation. Circulation Journal, 2014, 78, 2657-2664.	1.6	1
358	Bioresorbable drug-eluting stent implantation technique: In search of a magic recipe. Cardiovascular Revascularization Medicine, 2015, 16, 439-440.	0.8	1
359	CT coronary angiography increases diagnostic certainty in patients with stable chest pain. Evidence-Based Medicine, 2015, 20, 187-187.	0.6	1
360	Drug-eluting stent thrombosis in the treatment of chronic total coronary occlusions: Incidence, presentation and related factors. Data from the CIBELES trial. Revista Portuguesa De Cardiologia (English Edition), 2015, 34, 193-199.	0.2	1

#	Article	IF	CITATIONS
361	Ventricular Restoration: New Therapeutic Approaches. Revista Espanola De Cardiologia (English Ed), 2015, 68, 257-259.	0.6	1
362	Drug-eluting stent thrombosis in the treatment of chronic total coronary occlusions: Incidence, presentation and related factors. Data from the CIBELES trial. Revista Portuguesa De Cardiologia, 2015, 34, 193-199.	0.5	1
363	Unfavorable bioresorbable vascular scaffold resorption, a cause of restenosis?. Cardiovascular Revascularization Medicine, 2016, 17, 571-573.	0.8	1
364	Bioresorbable Vascular Scaffold Implantation. JACC: Cardiovascular Interventions, 2017, 10, 1865-1866.	2.9	1
365	ST-segment elevation mimicking myocardial infarction after hydrochloric acid ingestion: Acute caustic myocarditis. Journal of Cardiovascular Computed Tomography, 2017, 11, 70-71.	1.3	1
366	Serial optical coherence tomography assessment of malapposed struts after everolimus-eluting stent implantation. A subanalysis from the HEAL-EES study. Cardiovascular Revascularization Medicine, 2017, 18, 47-52.	0.8	1
367	Angina and Ischemia at 2 Years With Bioresorbable Vascular Scaffolds and Metallic Drug-eluting Stents. ESTROFA Ischemia BVS-mDES Study. Revista Espanola De Cardiologia (English Ed), 2018, 71, 327-334.	0.6	1
368	Tricuspid Percutaneous Repair With the MitraClip System: First Implant in Spain. Revista Espanola De Cardiologia (English Ed), 2018, 71, 976-977.	0.6	1
369	Corrección de fugas paravalvulares: buscando el equilibrio entre las técnicas quirúrgicas y percutáneas. Revista Espanola De Cardiologia, 2018, 71, 679-681.	1.2	1
370	Thrombotic and Bleeding Events After Percutaneous Coronary Intervention in Out-of-hospital Cardiac Arrest With and Without Therapeutic Hypothermia. Revista Espanola De Cardiologia (English Ed), 2019, 72, 433-435.	0.6	1
371	MitraClip Implantation for HemolyticÂAnemia Treatment After Surgical Mitral Valve Repair. JACC: Cardiovascular Interventions, 2020, 13, e85-e86.	2.9	1
372	Very-late restenosis of a magnesium-based resorbable scaffold. European Heart Journal, 2020, 41, 2602-2602.	2.2	1
373	Very Late Outcomes After StentÂlmplantation. Journal of the American College of Cardiology, 2020, 75, 605-607.	2.8	1
374	Impact of diabetes mellitus on vascular healing process after everolimus-eluting stent implantation: An optical coherence tomography study. Cardiovascular Revascularization Medicine, 2021, , .	0.8	1
375	Plaque modification in calcified chronic total occlusions: the PLACCTON study. Revista Espanola De Cardiologia (English Ed), 2021, 75, 213-213.	0.6	1
376	In-vivo measurements of heart ischemia using transoesophageal electrical impedance. IFMBE Proceedings, 2009, , 1163-1166.	0.3	1
377	The European Heart Journal and EuroIntervention: information and education in interventional cardiology. EuroIntervention, 2013, 9, 669-680.	3.2	1
378	New percutaneous interventions in heart failure. Minerva Cardioangiologica, 2019, 67, 145-162.	1.2	1

#	Article	IF	CITATIONS
379	Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. American Heart Journal, 2022, 246, 32-43.	2.7	1
380	Secondary revascularisation following intracoronary brachytherapy. EuroIntervention, 2009, 5 Suppl D, D121-6.	3.2	1
381	Clinical Impact of Medical Therapy Versus Revascularization in Patients With Chronic Coronary Total Occlusions. Journal of Invasive Cardiology, 2021, 33, E2-E8.	0.4	1
382	Commentary. Evidence-based Cardiovascular Medicine, 2005, 9, 46-47.	0.0	0
383	Letter by Brugaletta et al Regarding Article, "Interference of Drug-Eluting Stents and Endothelium-Dependent Coronary Vasomotion: Evidence for Device-Specific Responses― Circulation: Cardiovascular Interventions, 2009, 2, e1; author reply e2.	3.9	0
384	Letter by Brugaletta et al Regarding Article, "Vascular Reactivity and Flow Characteristics of Radial Artery and Long Saphenous Vein Coronary Bypass Grafts: A 5-Year Follow-Up― Circulation, 2011, 123, e412; author reply e414.	1.6	0
385	Comments on the ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. A Report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. Revista Espanola De Cardiologia (English Ed). 2012. 65. 125-130.	0.6	0
386	Organized Thrombus, Disorganized Heart. Circulation Journal, 2013, 77, 1152-1153.	1.6	0
387	Acute myocardial infarction, primary percutaneous coronary intervention and stent thrombosis in heart transplanted patient: Potential role of elevated coagulation factor VIII. Cor Et Vasa, 2014, 56, e311-e315.	0.1	0
388	Coronary Kinking in a Marathon Runner: A "Dangerous Liaison�. Revista Espanola De Cardiologia (English Ed), 2014, 67, 767.	0.6	0
389	Tortuosidad arterial coronaria en un corredor de maratón: ¿una «relación peligrosa»?. Revista Espanola De Cardiologia, 2014, 67, 767.	1.2	0
390	Nitric-oxide Coated Bioactive Titanium Stents: Safer and More Effective Than Second-generation Drug-eluting Stents?. Revista Espanola De Cardiologia (English Ed), 2014, 67, 511-513.	0.6	0
391	Platelet reactivity assessment with VerifyNow®: Substitute or complement for light transmission aggregometry?. International Journal of Cardiology, 2015, 178, 221-222.	1.7	0
392	Restauración ventricular: nuevos enfoques terapéuticos. Revista Espanola De Cardiologia, 2015, 68, 257-259.	1.2	0
393	Outcomes in the EXAMINATION trial – Authors' reply. Lancet, The, 2016, 387, 1998.	13.7	0
394	"No Country for Old Men―With ST-segment Elevation Myocardial Infarction. Revista Espanola De Cardiologia (English Ed), 2017, 70, 70-71.	0.6	0
395	Acute coronary syndrome in dextrocardia and situs inversus patient. Medicina ClÃnica (English) Tj ETQq1 1 0.78	4314 rgBT 0.2	Overlock 10
396	SÃndrome coronario agudo en paciente con dextrocardia y situs inversus. Medicina ClÃnica, 2017, 148, e69.	0.6	0

#	Article	IF	CITATIONS
397	Bioresorbable scaffolds: should we stay simple or go complex?. Cardiovascular Diagnosis and Therapy, 2017, 7, E7-E12.	1.7	0
398	Unravelling the pathophysiology of spontaneous coronary artery dissections. Revista Espanola De Cardiologia (English Ed), 2019, 72, 604-605.	0.6	0
399	How to SORT OUT an Additional Value From Noninferiority Stent Comparisons?. JACC: Cardiovascular Interventions, 2019, 12, 634-636.	2.9	0
400	Response by Ortega-Paz et al to Letter Regarding Article, "Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial― Circulation, 2020, 141, e748-e749.	1.6	0
401	Unravelling the best management strategy for older patients with acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 478-479.	1.0	0
402	Twoâ€year outcomes after percutaneous coronary intervention with drugâ€eluting stents or bareâ€metal stents in elderly patients with coronary artery disease. Catheterization and Cardiovascular Interventions, 2021, 97, E607-E613.	1.7	0
403	Acute coronary syndrome in nonagenarians: gender gap?. European Heart Journal: Acute Cardiovascular Care, 2021, 10, .	1.0	0
404	Outcomes in nonagenarians with acute coronary syndrome. Is medical treatment important?. European Journal of Preventive Cardiology, 2021, 28, .	1.8	0
405	Anatomical Fusion of MitraClip Device With Native Mitral Apparatus. JACC: Cardiovascular Interventions, 2021, 14, 1257-1258.	2.9	0
406	Long-term vascular function in CTO recanalization: A randomized clinical trial of ticagrelor vs. clopidogrel. Cardiovascular Revascularization Medicine, 2021, , .	0.8	0
407	Los implantes valvulares transcatéter en el 2021: una realidad cuyos lÃmites aún desconocemos. Medicina ClÃnica, 2021, 157, 535-536.	0.6	0
408	Combined left atrial appendage occlusion with other transseptal procedures: should we use the same transseptal puncture?. Revista Espanola De Cardiologia (English Ed), 2022, 75, 181-182.	0.6	0
409	Special Management of Diabetic Patients with STEMI. , 2010, , 183-196.		0
410	Scientific societies and clinical trials. EuroIntervention, 2010, 6, 185-188.	3.2	0
411	First-in-man, last in evidence?. EuroIntervention, 2013, 8, 999-1001.	3.2	0
412	Cardiac embolism after implantable cardiac defibrillator shock in non-anticoagulated atrial fibrillation: The role of left atrial appendage occlusion. World Journal of Cardiology, 2014, 6, 213.	1.5	0
413	Virtual Histology (VH) for Detecting Necrotic Core (NC). , 2015, , 1-20.		0
414	Double atrial septum or redundant Eustachian valve: procedural management during atrial septal defect occlusion. EuroIntervention, 2015, 11, e1-e2.	3.2	0

#	Article	IF	CITATIONS
415	Virtual Histology (VH) for Detecting Necrotic Core (NC). , 2016, , 877-896.		0
416	Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve. Moving to the percutaneous approach. EuroIntervention, 2017, 13, 1365-1366.	3.2	0
417	Treatment of device related thrombosis after left atrial appendage occlusion: Initial experience with low-dose apixaban. Cardiovascular Revascularization Medicine, 2021, , .	0.8	0
418	Percutaneous Coronary Intervention in Diabetic Patients. , 0, , .		0
419	Abstract from the ESTROFA registry. EuroIntervention, 2008, 4 Suppl C, C54-5.	3.2	0
420	Overlapping versus single long stents in long chronic total occlusions: insights of the Iberian CTO Registry. Minerva Cardiology and Angiology, 2022, , .	0.7	0
421	Transcatheter mitral valve repair in nonagenarians Journal of Geriatric Cardiology, 2022, 19, 90-94.	0.2	0
422	Atrial fibrillation and acute coronary syndromes in nonagenarians. European Heart Journal: Acute Cardiovascular Care, 2022, 11, .	1.0	0
423	Amphilimus- versus everolimus-eluting stents in patients with diabetes mellitus: 5-year follow-up of the RESERVOIR trial. Cardiovascular Revascularization Medicine, 2022, , .	0.8	0